Abstract
Solid tumors require angiogenesis for their growth and to form metastatsis. Many new cancer therapies are directed against tumor vessels. Radiation therapy is one of the most widely used treatments for a wide variety of tumors, and is thought to act by directly targeting clongenes, as well as was induce apoptosis of endothelial cells, and reduce angiogenesis. Vascular targeting agents are aimed specifically at the existing tumor vasculature. Anti-angiogenic agents target angiogenesis or new growth of tumor vessels. Recent preclinical studies have suggested that radiotherapy in combination with antiangiogenic agents enhances the therapeutic ratio of ioninzing radiation alone. Targeting tumor vasculature has strong biological rationale in radiation therapy and preclinical studies consistently show an increase in radiationsensitization with combined treatment. This review article explores the complex interaction between radiation therapy and antiangiogenic agents. Furthermore we discuss the efficacy of combined radiotherapy and AT1-R antagonist (TCV-116) on tumor associated angiogenesis.
Keywords: Angiogenesis, radiationtherapy, anti-angiogenic agents, combination therapy, angiotensin type 1 receptor
Current Signal Transduction Therapy
Title: Combined Effect of Anti-Angiogentic Agents, Angiotensin Type 1 Receptor Antagonists and Radiation Therapy
Volume: 5 Issue: 3
Author(s): Hideki Amano, Yuichiro Ohnuma, Yuzuru Niibe, Kazushige Hayakawa, Yukitoshi Satoh and Masataka Majima
Affiliation:
Keywords: Angiogenesis, radiationtherapy, anti-angiogenic agents, combination therapy, angiotensin type 1 receptor
Abstract: Solid tumors require angiogenesis for their growth and to form metastatsis. Many new cancer therapies are directed against tumor vessels. Radiation therapy is one of the most widely used treatments for a wide variety of tumors, and is thought to act by directly targeting clongenes, as well as was induce apoptosis of endothelial cells, and reduce angiogenesis. Vascular targeting agents are aimed specifically at the existing tumor vasculature. Anti-angiogenic agents target angiogenesis or new growth of tumor vessels. Recent preclinical studies have suggested that radiotherapy in combination with antiangiogenic agents enhances the therapeutic ratio of ioninzing radiation alone. Targeting tumor vasculature has strong biological rationale in radiation therapy and preclinical studies consistently show an increase in radiationsensitization with combined treatment. This review article explores the complex interaction between radiation therapy and antiangiogenic agents. Furthermore we discuss the efficacy of combined radiotherapy and AT1-R antagonist (TCV-116) on tumor associated angiogenesis.
Export Options
About this article
Cite this article as:
Amano Hideki, Ohnuma Yuichiro, Niibe Yuzuru, Hayakawa Kazushige, Satoh Yukitoshi and Majima Masataka, Combined Effect of Anti-Angiogentic Agents, Angiotensin Type 1 Receptor Antagonists and Radiation Therapy, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920292
DOI https://dx.doi.org/10.2174/157436210791920292 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Long Term Safety and Efficacy of Internal Carotid Artery Adventitial Stripping in Carotid Sinus Syndrome
Current Hypertension Reviews Lactic Acidosis, Hypotension, and Sensorineural Hearing Loss Following Intentional Metformin Overdose
Current Drug Safety Adipokines as Potential Biomarkers in the Neurorehabilitation of Obese Stroke Patients
Current Neurovascular Research Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology Impact of Periconceptional Undernutrition on the Development of the Hypothalamo-Pituitary-Adrenal Axis: Does the Timing of Parturition Start at Conception?
Current Drug Targets Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Serotonin (5-HT) Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity
Current Drug Targets Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Mediterranean Diet And Longevity: An Example Of Nutraceuticals?
Current Vascular Pharmacology Treat to Target in Spondyloarthritis: The Time has Come
Current Rheumatology Reviews Flavin Mono-Oxygenase (FMO) - The ‘Other’ Oxidase
Current Drug Metabolism Editorial: [Hot Topic: New Frontiers in Perinatal Pharmacology]
Current Medicinal Chemistry Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews Seizures Secondary to Bupropion Misuse/Abuse: Three Cases
Adolescent Psychiatry Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design